Paritaprevir (Standard)

• Description:

  Paritaprevir (Standard) is the analytical standard of Paritaprevir. This product is intended for research and analytical applications. Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) [1][2][3][4].

• UNSPSC:

  12352100

• Target:

  HCV; HCV Protease; Reference Standards; SARS-CoV

• Related Pathways:

  Anti-infection; Metabolic Enzyme/Protease; Others

• Field of Research:

  Infection

• Smiles:

  O=C ([C@]1 (NC ([C@@]2 ([H]) N3C[C@H] (OC4=C (C=CC=C5) C5=C6C (C=CC=C6) =N4) C2) =O) [C@H] (/C=C\CCCCC[C@H] (NC (C7=NC=C (C) N=C7) =O) C3=O) C1) NS (=O) (C8CC8) =O

• Molecular Formula:

  C40H43N7O7S

• Molecular Weight:

  765.88

• References & Citations:

  [1]Smith MA, et al. Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection. Drug Des Devel Ther. 2015 Nov 13;9:6083-94.|[2]Schnell G, et al. Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir/ritonavir. Antimicrob Agents Chemother. 2015 Aug 17. pii: AAC.01229-15.|[3]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.|[4]Menon RM, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015 Jul;63 (1) :20-9.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference Standards

• CAS Number:

  1216941-48-8